FDA expands AVTOZMA IV approval to include cytokine release syndrome
Written by
PharmaTimes
Published
0
comments
0
min
Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US